Cargando…

The somatostatin receptor 2 antagonist (64)Cu-NODAGA-JR11 outperforms (64)Cu-DOTA-TATE in a mouse xenograft model

Copper-64 is an attractive radionuclide for PET imaging and is frequently used in clinical applications. The aim of this study was to perform a side-by-side comparison of the in vitro and in vivo performance of (64)Cu-NODAGA-JR11 (NODAGA = 1,4,7-triazacyclononane,1-glutaric acid,4,7-acetic acid, JR1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rylova, Svetlana N., Stoykow, Christian, Del Pozzo, Luigi, Abiraj, Keelara, Tamma, Maria Luisa, Kiefer, Yvonne, Fani, Melpomeni, Maecke, Helmut R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906006/ https://www.ncbi.nlm.nih.gov/pubmed/29668724 http://dx.doi.org/10.1371/journal.pone.0195802

Ejemplares similares

The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist
por: Abiraj, Keelara, et al.
Publicado: (2018)

[(64)Cu]‐labelled trastuzumab: optimisation of labelling by DOTA and NODAGA conjugation and initial evaluation in mice
por: Schjoeth‐Eskesen, Christina, et al.
Publicado: (2015)

Synthesis and In Vitro Comparison of DOTA, NODAGA and 15-5 Macrocycles as Chelators for the (64)Cu-Labelling of Immunoconjugates
por: Maisonial-Besset, Aurélie, et al.
Publicado: (2022)

Radionuclide Cisternography with [(64)Cu]Cu-DOTA
por: Greiser, Julia, et al.
Publicado: (2023)

Comparison of the Effects of DOTA and NOTA Chelators on (64)Cu-Cudotadipep and (64)Cu-Cunotadipep for Prostate Cancer
por: Lee, Inki, et al.
Publicado: (2023)

Imaging of atherosclerosis with [(64)Cu]Cu-DOTA-TATE in a translational head-to-head comparison study with [(18)F]FDG, and Na[(18)F]F in rabbits
por: Grandjean, Constance E., et al.
Publicado: (2023)

Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [(64)Cu]Cu-DOTA-TOC
por: Vahidfar, Nasim, et al.
Publicado: (2022)

Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with (64)Cu Using NOTA and NODAGA
por: Tolmachev, Vladimir, et al.
Publicado: (2017)

[(68)Ga]Ga-NODAGA-E[(cRGDyK)](2) and [(64)Cu]Cu-DOTATATE PET Predict Improvement in Ischemic Cardiomyopathy
por: Follin, Bjarke, et al.
Publicado: (2023)

Synthesis of DOTA-pyridine chelates for (64)Cu coordination and radiolabeling of αMSH peptide
por: Yang, Hua, et al.
Publicado: (2021)

Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model
por: Ullrich, Martin, et al.
Publicado: (2016)

(64)Cu-ATSM/(64)Cu-Cl(2) and their relationship to hypoxia in glioblastoma: a preclinical study
por: Pérès, Elodie A., et al.
Publicado: (2019)

SAT-575 Radiolabeled Somatostatin Receptor Analog (86)Y-EB-TATE is Characterized by Superior Tumor Uptake Compared to (68)Ga-DOTA-TATE and (68)Ga-DOTA-JR11 in Thyroid Cancer Mice Models
por: Thakur, Shilpa, et al.
Publicado: (2019)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [(177)Lu]Lu-OPS201 Compared to the Agonist [(177)Lu]Lu-DOTA-TATE
por: Mansi, Rosalba, et al.
Publicado: (2021)

Recent Advances in (64)Cu/(67)Cu-Based Radiopharmaceuticals
por: Krasnovskaya, Olga O., et al.
Publicado: (2023)

(64)Cu-based Radiopharmaceuticals in Molecular Imaging
por: Zhou, Yeye, et al.
Publicado: (2019)

Positron Emission Tomography Imaging of CD105 Expression with a (64)Cu-Labeled Monoclonal Antibody: NOTA Is Superior to DOTA
por: Zhang, Yin, et al.
Publicado: (2011)

Synthesis and evaluation of (64)Cu-radiolabeled NOTA-cetuximab ((64)Cu-NOTA-C225) for immuno-PET imaging of EGFR expression
por: Xu, Xiaoxia, et al.
Publicado: (2019)

Harnessing (64)Cu/(67)Cu for a theranostic approach to pretargeted radioimmunotherapy
por: Keinänen, Outi, et al.
Publicado: (2020)

Theragnostic (64)Cu/(67)Cu Radioisotopes Production With RFT-30 Cyclotron
por: Lee, Jun Young, et al.
Publicado: (2022)

[(64)Cu]Cu-DOTATATE PET metrics in the investigation of atherosclerotic inflammation in humans
por: Jensen, Jacob K., et al.
Publicado: (2022)

Head-to-Head Comparison of (68)Ga-DOTA-TATE and (68)Ga-DOTA-JR11 PET/CT in Patients With Tumor-Induced Osteomalacia: A Prospective Study
por: Hou, Guozhu, et al.
Publicado: (2022)

Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
por: Opalinska, Marta, et al.
Publicado: (2023)

(64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry
por: Hansen, Anders E, et al.
Publicado: (2012)

(64)Cu-DOTA-Anti-CTLA-4 mAb Enabled PET Visualization of CTLA-4 on the T-Cell Infiltrating Tumor Tissues
por: Higashikawa, Kei, et al.
Publicado: (2014)

(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
por: Kurihara, Hiroaki, et al.
Publicado: (2015)

Evaluation of [(64)Cu]Cu-NOTA-PEG(7)-H-Tz for Pretargeted Imaging in LS174T Xenografts—Comparison to [(111)In]In-DOTA-PEG(11)-BisPy-Tz
por: Poulie, Christian B. M., et al.
Publicado: (2021)

Relationships between uptake of [(68)Ga]Ga-DOTA-TATE and absorbed dose in [(177)Lu]Lu-DOTA-TATE therapy
por: Stenvall, Anna, et al.
Publicado: (2022)

Preparation and Evaluation of ZD2 Peptide (64)Cu-DOTA Conjugate as a Positron Emission Tomography Probe for Detection and Characterization of Prostate Cancer
por: Han, Zheng, et al.
Publicado: (2019)

Effect of intratumoral administration on biodistribution of (64)Cu-labeled nanoshells
por: Xie, Huan, et al.
Publicado: (2012)

Integrated (64)Cu therapy for the peritoneal dissemination of gastrointestinal cancer
por: Kurihara, Hiroaki
Publicado: (2018)

Pilot Study of (64)Cu(I) for PET Imaging of Melanoma
por: Jiang, Lei, et al.
Publicado: (2017)

(64)Cu-DOTATOC PET-CT in Patients with Neuroendocrine Tumors
por: Mirzaei, Siroos, et al.
Publicado: (2019)

Effect of Liraglutide on Vascular Inflammation Evaluated by [(64)Cu]DOTATATE
por: Zobel, Emilie H., et al.
Publicado: (2021)

An abbreviated therapy-dosimetric equation for the companion diagnostic/therapeutic [(64/67)Cu]Cu-SARTATE
por: Laffon, Eric, et al.
Publicado: (2021)

Towards integration of (64)Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer
por: Jarrett, Angela M., et al.
Publicado: (2020)

Dose predictions for [(177)Lu]Lu-DOTA-panitumumab F(ab′)(2) in NRG mice with HNSCC patient-derived tumour xenografts based on [(64)Cu]Cu-DOTA-panitumumab F(ab′)(2) – implications for a PET theranostic strategy
por: Ku, Anthony, et al.
Publicado: (2021)

The Copper Radioisotopes: A Systematic Review with Special Interest to (64)Cu
por: Niccoli Asabella, Artor, et al.
Publicado: (2014)

Pilot Study of (64)CuCl(2) for PET Imaging of Inflammation
por: Jiang, Lei, et al.
Publicado: (2018)

PET Imaging of VEGFR with a Novel (64)Cu-Labeled Peptide
por: Hu, Kuan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5p8h9a98ufun153a6plpicahhu